{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:10:57Z","timestamp":1787890257544,"version":"build-2784847793"},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp;amp; Cancer"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fosaprepitant is non\u2010inferior to aprepitant in adults receiving highly emetogenic chemotherapy (HEC). We evaluated whether fosaprepitant is non\u2010inferior to aprepitant in children receiving HEC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this open\u2010label, non\u2010inferiority trial, children aged 5\u201318\u00a0years, receiving their first cycle of HEC, were randomized 1:1 to the fosaprepitant or aprepitant group. The fosaprepitant group received a single intravenous dose of 4\u00a0mg\/kg (max 150\u00a0mg). The aprepitant group received oral aprepitant capsules (weight 15 to &lt;30\u00a0kg: 80\u00a0mg Days 1\u20133; weight \u226530\u00a0kg, or age \u226512\u00a0years: 125\u00a0mg Day 1, 80\u00a0mg Days 2 and 3). Both groups received ondansetron and dexamethasone. The primary outcome was the complete response (CR) rate of vomiting during the acute phase (AP) with a non\u2010inferiority margin of 15%. Secondary outcomes included CR rates in the delayed (DP) and overall phases (OP), grade of vomiting, incidence and severity of nausea, and adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 279 children were included in the modified intention\u2010to\u2010treat analysis (fosaprepitant group: 140; aprepitant group: 139). In AP, the difference of CR rate between fosaprepitant [76 (54.3%)] and aprepitant groups [84 (60.4%)] was \u22126.1% [90% CI: \u221215.7% to +3.6%], with the lower limit exceeding \u221215%, failing to establish non\u2010inferiority. The CR rate with fosaprepitant versus aprepitant was 62.1% (\n                      <jats:italic>n<\/jats:italic>\n                      = 87) versus 65.5% (\n                      <jats:italic>n<\/jats:italic>\n                      = 91) in DP (difference: \u20133.4%; 90% CI: \u201312.7% to 6.1%) and 42.9% (\n                      <jats:italic>n<\/jats:italic>\n                      = 60) versus 49.6% (\n                      <jats:italic>n<\/jats:italic>\n                      = 69) in the OP (difference: \u20136.7%; 90% CI: \u201316.5% to 3.1%). Grade of vomiting, incidence and severity of nausea, and adverse effects were similar between the two groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Non\u2010inferiority of fosaprepitant compared to aprepitant was not demonstrated in children undergoing their first cycle of HEC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>Clinical Trials Registry, India (CTRI\/2019\/05\/019082).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/1545-5017.70171","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T11:01:21Z","timestamp":1773399681000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Intravenous Fosaprepitant Versus Oral Aprepitant for Children Receiving Highly Emetogenic Chemotherapy: An Investigator\u2010Initiated Randomized, Open\u2010Label, Non\u2010Inferiority Trial"],"prefix":"10.1002","volume":"73","author":[{"given":"Azgar Abdul","family":"Rasheed","sequence":"first","affiliation":[{"name":"Department of Medical Oncology KIMS Cancer Centre  Trivandrum India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuvadeep","family":"Ganguly","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)  Puducherry India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2939-5400","authenticated-orcid":false,"given":"Manraj Singh","family":"Sra","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhosh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences (AIIMS)  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Batra","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences (AIIMS)  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepam","family":"Pushpam","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences (AIIMS)  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreenivas","family":"Vishnubhatla","sequence":"additional","affiliation":[{"name":"Department of Biostatistics All India Institute of Medical Sciences (AIIMS)  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwati S.","family":"Pillai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences (AIIMS)  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu Theresa","family":"Joison","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences (AIIMS)  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetambri","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences (AIIMS)  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Bakhshi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences (AIIMS)  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph17050616"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2714-9"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70061-6"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01296"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30001"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27551"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07287-w"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.7859"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/ped.13780"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13322"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216631408"},{"key":"e_1_2_9_13_1","unstructured":"\u201cGood Clinical Practice \u201dFDA last updated November 2024 https:\/\/www.fda.gov\/about\u2010fda\/center\u2010drug\u2010evaluation\u2010and\u2010research\u2010cder\/good\u2010clinical\u2010practice."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03635-5"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00134"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00871"},{"key":"e_1_2_9_17_1","unstructured":"\u201cNCI Dictionaries \u201d accessed December 27 2025 https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer\u2010terms\/def\/retch."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27646"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13280"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780040211"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.21037\/tp-23-598"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-024-05766-7"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-022-04436-1"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27690"},{"key":"e_1_2_9_26_1","unstructured":"\u201cIvemend \u201dEuropean Medicines Agency (EMA) last updated November2025 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ivemend."},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26542"},{"issue":"2","key":"e_1_2_9_28_1","first-page":"127","article-title":"Aprepitant and Fosaprepitant Use in Children and Adolescents at an Academic Medical Center","volume":"19","author":"Shillingburg A.","year":"2014","journal-title":"J"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24901"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1545-5017.70171","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/1545-5017.70171","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1545-5017.70171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T12:27:16Z","timestamp":1779539236000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/1545-5017.70171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/1545-5017.70171"],"URL":"https:\/\/doi.org\/10.1002\/1545-5017.70171","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"2025-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70171"}}